SCHEMBL3841201

SCHEMBL3841201

CC(C)CCCCN=C=O

nearest known ligand 0.40

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.40
BLM P54132 1/20 0.30
ALDH1A1 P00352 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28994512 0.98 LMNA (0.39) LMNA
SCHEMBL2151634 0.98 LMNA (0.39) LMNA
SCHEMBL19468519 0.98 LMNA (0.39) LMNA
SCHEMBL11171519 0.98 LMNA (0.39) LMNA
SCHEMBL3842284 0.98 LMNA (0.39) LMNA
SCHEMBL19468488 0.98 LMNA (0.39) LMNA
SCHEMBL8984323 0.98 LMNA (0.39) LMNA
SCHEMBL9000968 0.98 LMNA (0.39) LMNA
SCHEMBL30229872 0.98 LMNA (0.39) LMNA
SCHEMBL29787970 0.98 LMNA (0.39) LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118027894-A Adhesive, negative electrode slurry and lithium ion battery 深圳好电科技有限公司 2024-05-14 CN claimed
CN-118027894-A Adhesive, negative electrode slurry and lithium ion battery 深圳好电科技有限公司 2024-05-14 CN disclosed
US-20230374194-A1 POLYISOCYANATE COMPOSITION, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF WANHUA CHEMICAL GROUP CO LTD (CN) 2023-11-23 US disclosed
CN-111269128-B Synthesis method of 1,1' - (hexa-2, 4-diyne-1, 6-diyl) bis (3-alkyl urea) compound 苏州爱玛特生物科技有限公司 2022-08-30 CN disclosed
US-20210317324-A1 MULTILAYER COATING FILM AND METHOD FOR PRODUCING THE SAME ASAHI KASEI KABUSHIKI KAISHA (JP) 2021-10-14 US disclosed
CN-111269128-A Synthesis method of 1, 1' - (hexa-2, 4-diyne-1, 6-diyl) bis (3-alkyl urea) compound 苏州爱玛特生物科技有限公司 2020-06-12 CN disclosed
EP-2111443-A2 BENEFIT AGENT DELIVERY COMPOSITIONS The Procter and Gamble Company (US) 2009-10-28 EP disclosed
US-7595403-B2 Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
US-7595403-B2 Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors ELI LILLY AND COMPANY (US) 2009-09-29 US disclosed
EP-1610779-B1 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS LILLY CO ELI (US) 2009-09-09 EP disclosed
US-7217727-B2 Phospholipase inhibitors ELI LILLY AND COMPANY (US) 2007-05-15 US disclosed
US-7217727-B2 Phospholipase inhibitors ELI LILLY AND COMPANY (US) 2007-05-15 US disclosed
US-20060211755-A1 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors ELI LILLY AND COMPANY PATENT DIVISION (US) 2006-09-21 US disclosed
US-20060116409-A1 Phospholipase inhibitors ELILILLY AND COMPANY 2006-06-01 US disclosed
EP-1615900-A1 BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-01-18 EP disclosed
EP-1613608-A1 PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-01-11 EP disclosed
EP-1610779-A1 3-OXO-1,3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-01-04 EP disclosed
WO-2004093872-A1 3-OXO-1, 3-DIHYDRO-INDAZOLE-2-CARBOXYLIC ACID AMIDE DERIVATIVES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed
WO-2004094394-A1 BENZISOTHIAZOL-3-ONE-CARBOXYLIC ACID AMIDES AS PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed
WO-2004094393-A1 PHOSPHOLIPASE INHIBITORS ELI LILLY AND COMPANY (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211755-A1 3-oxo-1, 3-dihydro-indazole-2-carboxylic acid amide derivatives as phospholipase inhibitors C5AR2, C3AR1, C5AR1 LMNA 924/4885BLM 1089/4885ALDH1A1 2776/4885
US-20060116409-A1 Phospholipase inhibitors LIPG, PNLIP, LIPC LMNA 884/4885BLM 1160/4885ALDH1A1 1347/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.